Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care (PRICE)

May 8, 2017 updated by: Adam Kingeter, Vanderbilt University

Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care: Physician Awareness of ICU Charge Environment: The PRICE Study

To investigate the effects of the availability of daily patient-related charges on ordering patterns of health care ordering providers and cost containment in the Intensive Care Unit (ICU) setting.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Ordering providers include resident, fellow and attending physicians, as well as mid level providers such as Nurse Practitioners (NP's) and Physician Assistants (PA's). The investigators have developed a dashboard that displays both daily and cumulative charges related to laboratory, pharmacy, radiology, and other services for all patients admitted to Vanderbilt ICU's. Using this dashboard an ICU ordering provider is able to see not only the total daily charges for the previous 24 hours, but also the sum of all charges for that patient's current ICU admission. In addition, a "snapshot" overview tab is available for each patient that displays a day by day trend of the overall charges of the ICU stay for the patient, top 5 most expensive lab/radiology/pharmacy charges, previous 24 hour charges, and the total ICU number of chest x-ray, Complete Blood Count (CBC), Basic Metabolic Panel (BMP), Electrocardiogram (EKG), and Arterial Blood Gas (ABG) charges to the patient. The ordering provider is able to query the database of the dashboard for information regarding individual laboratory and drug charges, as well as view trajectory of total charges for a given patient. This dashboard allows for unprecedented transparency regarding the cost of care for patients in an ICU. Patients are identified in the dashboard by Medical Record Number (MRN), ICU bed, and initials only so as to protect their identity.

AIM 1: To evaluate the effects of introducing charge transparency to ordering providers via a charge dashboard and associated printed synopsis on average charge per patient per day in the Vanderbilt ICUs.

We intend to study the effect of charge transparency to ordering providers on average charge per patient per day by conducting a prospective, self-controlled by unit, multiple cross-over trial. We will divide the study period into four 12-week blocks with two blocks of "charge transparency" and two blocks of "no transparency." Each unit will be assigned to alternating blocks of "transparency" and "no transparency" during the study with each unit on the same schedule so as to prevent cross contamination.

For months during which access is granted, all ordering providers in the study ICU will be granted access to the ICU charge dashboard following a brief orientation. In addition a password protected, unit specific iPad will be provided to each study unit. The iPad will enable point of care access to the patient specific snapshot information, as well as easily incorporate the dashboard information into clinical care.

AIM 2: To evaluate the effects of utilization of a charge dashboard on ordering patterns of providers and cost containment in the Vanderbilt ICUs.

In addition to studying the effect of charge transparency on patient ICU charges, we also intend to study the effect of charge transparency on resource utilization, namely routine laboratory and radiology tests. As surrogate markers for routine laboratory utilization we will measure average number of Comprehensive Blood Count (CBC) and Basic Metabolic Panel (BMP) tests per patient per day, and as surrogate markers for routine radiology utilization we will use average number of chest x-rays per patient per day.

Study Type

Observational

Enrollment (Actual)

10720

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients admitted to the Vanderbilt University Medical Center Cardiovascular, Surgical, Burn, Medical and Neuroscience ICUs will be included

Description

Inclusion Criteria:

  • All patients admitted to the Vanderbilt University Medical Center Cardiovascular, Surgical, Burn, Medical and Neuroscience ICUs will be included

Exclusion Criteria:

  • There are no exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Charge transparency
Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
Providers caring for patients in the "Charge Transparency" cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs
Without charge transparency
Providers without access to patient specific charge data

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average charge per patient per day ($)
Time Frame: 12 week block
Sum hospital charges for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average charge per patient per day in the ICU during the study period for each cohort.
12 week block

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average number of Basic Metabolic Panels per patient per day
Time Frame: 12 week blocks
Sum total of basic metabolic panels for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of basic metabolic panels per patient per day in the ICU during the study period for each cohort.
12 week blocks
Average number of complete blood counts per patient per day
Time Frame: 12 weeks
Sum total of complete blood counts for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of complete blood counts per patient per day in the ICU during the study period for each cohort.
12 weeks
Average number of chest x-rays per patient per day
Time Frame: 12 weeks
Sum total of portable chest x-rays for each study unit during the 12 week block will be divided by total number of patients admitted to the study unit during that time, and again by 84 days to obtain average number of chest x-rays per patient per day in the ICU during the study period for each cohort.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Adam J Kingeter, MD, Vanderbilt University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 2, 2015

Primary Completion (Actual)

October 3, 2016

Study Completion (Actual)

October 3, 2016

Study Registration Dates

First Submitted

June 11, 2015

First Submitted That Met QC Criteria

June 18, 2015

First Posted (Estimate)

June 19, 2015

Study Record Updates

Last Update Posted (Actual)

May 9, 2017

Last Update Submitted That Met QC Criteria

May 8, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 150722

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intensive Care

Clinical Trials on Charge Transparency

3
Subscribe